Biotechnology
Commented by Carsten Mainitz on July 26th, 2021 | 13:55 CEST
BioNTech, Cardiol Therapeutics, CureVac - What is next?
Are you smiling or shaking your head? Both are easily understandable reactions that investors might have in light of the latest statements from the Deutsches Aktien Institut (DAI). The DAI calls for better conditions for IPOs of growth companies to prevent such companies from migrating to foreign stock exchanges, as happened with BioNTech, among others. "Especially companies with specialized business models and high financing needs are dependent on foreign investors," explained Uta-Bettina von Altenbockum. However, this is not a new phenomenon either. Other countries have been creating better framework conditions for corporations and better tax incentives for investors for a long time. Own goal. What opportunities are there?
Read
Commented by André Will-Laudien on July 23rd, 2021 | 11:37 CEST
CureVac, XPhyto Therapeutics, BioNTech, NanoRepro - Continuous testing or vaccination or both?
Public confusion reigns. The pandemic seems to be locked in chains over the summer, and the population is happy about initial relief with incidences below 10. But now, the first vacationers are already coming back, partly from risk or mutation areas and have to go for testing again as vaccinated persons. It is often forgotten that even those who have been fully vaccinated can be carriers of the virus and can also fall ill, so it should be clear to everyone that personal protective measures must continue to be kept high. Our life with the COVID virus will last much longer than many want to believe...
Read
Commented by Nico Popp on July 20th, 2021 | 13:42 CEST
Siemens Healthineers, Cardiol Therapeutics, CureVac: Where there is music to be heard by the end of the year
Health is the highest good. Anyone who has ever experienced people having the "plug pulled" on them overnight can undoubtedly relate to this truism. Fortunately, medicine in this country is able to provide a quick remedy. A wide range of options are available for both diagnosis and therapy. In addition to laboratory analyses, imaging procedures also ensure that disease patterns can be narrowed down and, thus, treatments can be carried out in a targeted manner. Although our drugs are already powerful, new, more innovative approaches are emerging all the time. This development is also benefiting investors.
Read
Commented by Armin Schulz on July 19th, 2021 | 11:11 CEST
BioNTech, Defence Therapeutics, Siemens Healthineers - Winning the fight against cancer
There are over 200 different types of cancer where degenerate cells begin to form tumors. The cost of the disease is estimated at USD 1,160,000,000,000 worldwide. It is no wonder that a lot of money goes into researching cancer drugs. Whoever makes the breakthrough here can make a lot of money. It would be desirable that one of the three companies presented today could find a solution, as that could save 9.6 million people a year. But it is not only drugs that promise profits but also prevention and diagnostics. Today we highlight three companies that have joined the fight against cancer.
Read
Commented by Carsten Mainitz on July 13th, 2021 | 07:55 CEST
BioNTech, Defence Therapeutics, Formycon - Which biotech stock suits which investor?
Corona is and remains the threat of the hour. In this respect, it is not surprising that the papers of the German vaccine pioneer BioNTech have gone on a fabulous journey. Other companies are still trying to jump on this bandwagon, too. For example, both Canada's Defence Therapeutics and Munich-based Formycon AG are researching a Covid-19 vaccine. However, these developments are at very different stages. In addition, the further product spectrum differs significantly in some cases. But which share is the right one for the portfolio? We took a closer look at the three dissimilar siblings.
Read
Commented by Carsten Mainitz on July 12th, 2021 | 10:07 CEST
CureVac, XPhyto Therapeutics, Paion - Where are the turning points?
"Opportunity and risk are two sides of the same coin", that is to say, with great potential returns, there is also the risk of incurring significant price losses. The biotechnology sector, in particular, offers investors a broad universe in which to find lucrative investments. We present three exciting ideas below. Who is winning the race?
Read
Commented by Stefan Feulner on July 8th, 2021 | 13:18 CEST
BioNTech, Defence Therapeutics, Moderna - The wheel keeps turning
After a hesitant start, Germany is making good progress with vaccinations. Around 47.5 million people, or 57.1% of the total population, have been vaccinated at least once. The number of fully vaccinated people rises to 39.9%. Rosy prospects for the summer in the republic. But now comes the Delta variant. According to initial studies, it is more resistant to the vaccines currently on the market than other variants. Research is continuing, and new manufacturers are entering the market to participate in the billion-dollar business.
Read
Commented by André Will-Laudien on July 6th, 2021 | 13:49 CEST
Defence Therapeutics, CureVac, BioNTech - Successful therapy, earn billions!
Since we have a large number of health-threatening issues on the table, there are just as many biotech and pharma companies that have taken up the cause of researching and combating them. Many of them are publicly traded or in the early stages of venture funding. Investors are spoiled for choice; besides good analysis, they need a fair amount of intuition and luck to find the right stock that will truly become a 500-percenter. The cancer research company CEL-SCI recently disappointed, as did the COVID vaccine expert CureVac - both shares ended in a price disaster. The question remains - which horses are the right ones?
Read
Commented by Nico Popp on July 6th, 2021 | 11:34 CEST
Bayer, XPhyto Therapeutics, Pfizer: Here comes the blockbuster of the 4th wave
Hygiene sluices, rapid tests, disinfectants and vaccines - what was more familiar to laboratory staff or doctors a few years ago has become our daily bread since the outbreak of the pandemic. It stands to reason that the new normality would also leave its mark on the stock market. Indeed, the shares of major pharmaceutical companies have already risen. However, there are still newcomers with considerable potential. Growth companies, in particular, could benefit from the hype surrounding hygiene and health.
Read
Commented by Carsten Mainitz on June 30th, 2021 | 12:59 CEST
CureVac, Cardiol Therapeutics, MorphoSys - Here it is going powerfully upwards!
Biotech stocks offer investors not only an exciting but also a very profitable investment environment. But the sector is also attractive for traders due to its high volatility. CureVac took a beating recently as the efficacy of its Corona vaccine disappointed. The price of MorphoSys falls despite good news and positive analyst comments. The Canadian Cardiol Therapeutics could be on the verge of a revaluation. Where can the most significant gains be made in the short term?
Read